Ubs Group Ag Citius Pharmaceuticals, Inc. Call Options Transaction History
Ubs Group Ag
- $397 Billion
- Q1 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding CTXR
# of Institutions
73Shares Held
26.8MCall Options Held
0Put Options Held
0-
Black Rock Inc. New York, NY8.73MShares$5.93 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA7.01MShares$4.76 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA2.95MShares$2 Million0.0% of portfolio
-
State Street Corp Boston, MA2.21MShares$1.5 Million0.0% of portfolio
-
Northern Trust Corp Chicago, IL1.12MShares$761,7960.0% of portfolio
About Citius Pharmaceuticals, Inc.
- Ticker CTXR
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 146,130,000
- Market Cap $99.4M
- Description
- Citius Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development and commercialization of critical care products focusing on anti-infective products in adjunct cancer care, prescription products, and mesenchymal stem cell therapy. The company is developing five proprietary products comprising Mino-Lok, an antibiotic l...